Sikander Ailawadhi
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments 165
- Chronic Myeloid Leukemia Treatments 30
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 78
- Oncology top 2%
- Cancer Treatment and Pharmacology 36
- CAR-T cell therapy research 28
- Peptidase Inhibition and Analysis 25
-
- Lymphoma Diagnosis and Treatment 31
- Molecular Biology top 10%
- Protein Degradation and Inhibitors 66
- Co-authors
- Asher Chanan‐KhanTaimur SherAneel PaulusVivek RoyDongyun YangAbhisek SwaikaPedram RazaviRyan D. Frank
- Cited by
- HematologyGeneticsOncology
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Sikander Ailawadhi
288 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 110
- Hematology 1.7k
- Genetics 620
- Oncology 1.4k
- Pathology and Forensic Medicine 368
- Molecular Biology 1.1k
Countries citing papers authored by Sikander Ailawadhi
This map shows the geographic impact of Sikander Ailawadhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sikander Ailawadhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sikander Ailawadhi more than expected).
Fields of papers citing papers by Sikander Ailawadhi
This network shows the impact of papers produced by Sikander Ailawadhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sikander Ailawadhi. The network helps show where Sikander Ailawadhi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sikander Ailawadhi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 3 | |
| 6 | 2024 | 5 | |
| 7 | 2024 | 7 | |
| 8 | 2024 | 1 | |
| 9 | 2023 | 2 | |
| 10 | 2023 | 13 | |
| 11 | 2023 | 10 | |
| 12 | 2022 | 2 | |
| 13 | 2022 | 17 | |
| 14 | 2020 | 100 | |
| 15 | 2019 | 44 | |
| 16 | 2019 | 31 | |
| 17 | 2018 | 10 | |
| 18 | 2017 | 0 | |
| 19 | 2017 | 1 | |
| 20 | 2017 | 1 |
About Sikander Ailawadhi
Sikander Ailawadhi is a scholar working on Hematology, Genetics and Oncology, having authored 312 papers that have together received 3.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (165 papers), Chronic Lymphocytic Leukemia Research (78 papers), Protein Degradation and Inhibitors (66 papers), Cancer Treatment and Pharmacology (36 papers), Lymphoma Diagnosis and Treatment (31 papers), Chronic Myeloid Leukemia Treatments (30 papers), CAR-T cell therapy research (28 papers) and Peptidase Inhibition and Analysis (25 papers). The work is most often cited by research in Hematology (1.7k citations), Genetics (620 citations) and Oncology (1.4k citations). Sikander Ailawadhi has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Asher Chanan‐Khan, Taimur Sher, Aneel Paulus, Vivek Roy, Dongyun Yang, Abhisek Swaika, Pedram Razavi, Ryan D. Frank, Wendy Cozen and Pooja Advani. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Cancer Journal, British Journal of Haematology and Cancer Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.